It’s the wave of the British-Swedish pharmaceutical which is gathering up causing a rage in the Indian Pharma industry, where the firm plans to double-up its workforce and seek the launch of all its global brands in the country in the coming two years. At the same time, the company is releasing two diabetes drugs under a tie-up with Bristol-Myers Squibb.

The pharmaceutical major deals in cardiovascular drugs and has recently increased its workforce and plans to add another 200, says Anandh Balasundaram, managing director at AstraZeneca Pharma India.

Balasundaram further adds that, it’s the need of the hour as the nation requires cardiovascular medicines and thus it will be launching at least 7-8 products which be a concoction of  patented and India specific generics.

AstraZeneca who earlier had an agreement with the Bristol-Myers Squibb of India plans to work upon the vaccines for the type 2 diabetes. And soon the company shall be launching a second diabetes drug, dapagliflozin in India. The prior medicinal pill Onglyza (saxagliptin) for diabetes is working for the diabetics and competes with Merck’s Januvia in India.